Breaking news on irritable bowel syndrome
(IBS)
N30 Pharma Initiates Phase 1 Trials Of Novel Reductase Inhibitor published
Thu, 09 Sep 2010 03:00:00 PDT
N30 Pharmaceuticals, LLC announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). N6022 is the first GSNOR inhibitor to be administered to human beings...
Low Bone Mineral Density Common In Children And Teenagers With Inflammatory Bowel Disease published
Tue, 24 Aug 2010 01:00:00 PDT
A thesis from the University of Gothenburg (Sweden) is the first in Scandinavia to study the occurrence of low bone mineral density in children and teenagers with inflammatory bowel disease. Half of the patients in the study showed signs of low bone mineral density...
Stress Management, Diet Changes Improve Irritable Bowel Syndrome Symptoms published
Mon, 23 Aug 2010 04:00:00 PDT
When persistent cramping, abdominal pain, bloating, gas, diarrhea and constipation are causing distress and frequent bathroom trips, the next stop should be a visit to the doctor. These symptoms, commonly caused by irritable bowel syndrome (IBS), often can be minimized with diet and lifestyle changes...
Proof That Irritable Bowel Syndrome Is Not In Your Head published
Sat, 21 Aug 2010 00:00:00 PDT
Irritable bowel syndrome makes life miserable for those affected -- an estimated ten percent or more of the population. And what irritates many of them even more is that they often are labeled as hypochondriacs, since physical causes for irritable bowel syndrome have never been identified...
UCD Scientists Pinpoint Potential Key Regulator In Battle To Target Inflammatory Bowel Disease (IBD) published
Thu, 05 Aug 2010 04:00:00 PDT
Research into inflammatory bowel disease (IBD) led by UCD Conway Institute scientists with national and international collaborators has identified a key regulator involved in maintaining the functional integrity of the gut lining...
N30 Pharma Announces FDA Approval To Initiate Phase 1 Clinical Trial For First-in-Class Drug published
Thu, 05 Aug 2010 04:00:00 PDT
N30 Pharmaceuticals, LLC announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD)...
Scientists Target Possible Cause Of One Form Of Bowel Disease published
Wed, 04 Aug 2010 03:00:00 PDT
A possible cause of irritable bowel syndrome has been traced to a small piece of RNA that blocks a substance protecting the colon membrane, leading to hostile conditions that can produce diarrhea, bloating and chronic abdominal pain. New research shows that this RNA segment sends signals that stop the activity of the gene that produces glutamine, an amino acid...
Study Finds Structural Brain Alterations In Patients With Irritable Bowel Syndrome published
Fri, 23 Jul 2010 02:00:00 PDT
A large academic study has demonstrated structural changes in specific brain regions in female patients with irritable bowel syndrome (IBS), a condition that causes pain and discomfort in the abdomen, along with diarrhea, constipation or both. A collaborative effort between UCLA and Canada's McGill University, the study appears in the July issue of the journal Gastroenterology...
A Guide For Vaccinating The IBD Patient; Findings On Impact Of Gluten-Free Diet In Adult Celiac Patients published
Wed, 23 Jun 2010 02:00:00 PDT
A guide for vaccinating the Inflammatory Bowel Disease patient, and studies looking at the impact of a gluten-free diet on adults with celiac disease and the relationship between cognitive factors and treatment response in patients with functional bowel disorders, like IBS, are among the highlights of the June issue of The American Journal of Gastroenterology...
Lubiprostone Successfully Completes Phase 3 Efficacy Trial In Japanese Patients Suffering From Chronic Idiopathic Constipation published
Thu, 10 Jun 2010 00:00:00 PDT
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) and Abbott (NYSE:ABT) today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data...
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment Of Non-Constipation Irritable Bowel Syndrome published
Thu, 10 Jun 2010 00:00:00 PDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXANŽ (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating...
Symptoms Of Digestive Disorders Alleviated By Probiotic Found In Breast Milk published
Fri, 04 Jun 2010 00:00:00 PDT
New research published in the FASEB Journal suggests that Lactobacillus reuteri immediately affects nerves in the gut, explaining how probiotics work Here's another reason to breast feed your baby: Canadian researchers have discovered how a probiotic found in breastmilk reduces or eliminates painful cramping in the gut...
Narrow-Band Imaging A Useful Tool To Detect In Vivo Angiogenesis In IBD Patients published
Fri, 21 May 2010 05:00:00 PDT
Angiogenesis plays a crucial role in neoplastic and non-neoplastic chronic inflammatory disorders, including inflammatory bowel diseases (IBD). Several reports have shown that blockade of angiogenesis in preclinical models of IBD is a promising new therapeutic approach. Visualize angiogenesis in vivo may represent the first step for such a therapeutic approach...
Can Choir Singing Improve Irritable Bowel Syndrome? published
Wed, 19 May 2010 02:00:00 PDT
A Swedish investigation has compared choir singing and group discussion in irritable bowel syndrome in the current issue of Psychotherapy and Psychosomatics. Singing in a choir is very popular in the Nordic countries. This activity has been associated with increased longevity, and it induces feelings of relaxation and energy...
Rotavirus Vaccine Greatly Reduces Hospitalizations For Acute Gastroenteritis In Children published
Sat, 15 May 2010 00:00:00 PDT
Vaccinating infants against rotavirus, a leading cause of severe diarrhea and dehydration among babies and young children, was associated with a dramatic decline in U.S. hospitalization rates for acute gastroenteritis. The findings appear in a study, now available online (http://www.journals.uchicago.edu/doi/abs/10.1086/652403), published in the June 1 issue of The Journal of Infectious Diseases...
Even The Most Severe Symptoms Rapidly Relieved By Self-Directed Behavioral IBS Treatment published
Thu, 13 May 2010 05:00:00 PDT
Nearly one-third of patients with irritable bowel syndrome (IBS) who underwent a novel behavior treatment developed by a University at Buffalo behavioral scientist achieved significant relief within four weeks of beginning treatment...
Researchers Report Mild-Mannered Metabolic Helper Rushes To Fight Invading Viruses published
Mon, 10 May 2010 02:00:00 PDT
Within cells, an ancient antiviral duo can deliver a one-two knockout to thwart invading viruses, report researchers who have just unmasked the cellular sidekick that throws the first punch. The findings mean scientists must rethink the design of antiviral immunity and how the body fends off viruses of all types, including influenza and HIV...
Lexicon Presents Positive Outcome In IBS Patients Treated With LX1031 And Data Supporting Mechanism Of Action published
Fri, 07 May 2010 02:00:00 PDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana...
Researchers Discover New Genetic Candidates For Irritable Bowel Syndrome published
Wed, 05 May 2010 02:00:00 PDT
Most people associate serotonin with brain neurology, but over 95 percent of the body's serotonin occurs in the gastrointestinal tract, which has a complex neuronal circuit that has been called "the second brain" of the body. Now a Mayo Clinic research team has identified a number of genetic variants in serotonin genes that impact irritable bowel syndrome or IBS...
Ironwood And Forest Present Positive Linaclotide Results From Two Pivotal Phase 3 Trials In Patients With Chronic Constipation published
Wed, 05 May 2010 02:00:00 PDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) presented Phase 3 clinical trial results assessing the efficacy and safety of the investigational drug linaclotide in patients with chronic constipation (CC)...
Antibiotic Prevents IBS Symptoms For Weeks After Final Dose published
Wed, 05 May 2010 00:00:00 PDT
A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug...
Patients With IBS Commonly Use Narcotics published
Tue, 04 May 2010 03:00:00 PDT
Doctors often unnecessarily treat irritable bowel syndrome (IBS) with narcotics, according to a study led by University of North Carolina at Chapel Hill researchers. "This course of treatment is generally inadvisable because it does not improve functional status and may have adverse long term effects," said study lead author Spencer D...
Albireo Announces Positive Results From A Study With A3309 In Patients With Chronic Constipation published
Fri, 30 Apr 2010 03:00:00 PDT
Albireo announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC)...
Outstanding Young Gastroenterologists Receive AGA Foundation 2010 Research Scholars Award published
Thu, 29 Apr 2010 00:00:00 PDT
The Foundation for Digestive Health and Nutrition (FDHN) has announced the 2010 American Gastroenterological Association (AGA) Foundation research scholars. The grants have been awarded to seven outstanding young gastroenterologists who promise to make significant strides in the field of gastrointestinal research...
Severe IBS Symptoms Relieved By Non-Medical Treatment published
Wed, 28 Apr 2010 05:00:00 PDT
A significant proportion of irritable bowel syndrome (IBS) patients treated with cognitive behavior therapy have a positive response within four weeks of treatment, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute...
)
|
|
